Sanofi en­lists Ada­gene and its 'mask­ing' tech to de­vel­op new I/O drugs, in a deal po­ten­tial­ly worth $2.5B

Sanofi is putting to­geth­er a new, multi­bil­lion dol­lar deal aim­ing to leap in­to the next gen­er­a­tion of im­muno-on­col­o­gy.

The French phar­ma signed a col­lab­o­ra­tion with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER